Astor's growth potential remains attractive, although order timing warrants a more cautious
earnings outlook. We cut estimates and our PT to reflect sustained order intake weakness and
delivery risks, while retaining BUY. Q3 should bring sequential margin recovery, with Industry,
Ammunity and NSG supporting growth beyond near-term procurement delays.
LÄS MER
